VTRS - Obesity Drug Wegovy's Triumph to Catapult Novo Holdings In Golden Era Of Wealth Boost | Benzinga
Novo Holdings, the controlling shareholder of Novo Nordisk A/S (NYSE: NVO), is bracing for a significant influx of capital stemming from the thriving success of the weight-loss drug Wegovy.
Kasim Kutay, CEO of Novo Holdings, projects a financial boon exceeding $12 billion in the upcoming years, elevating the investment firm and its parent foundation into prominent roles within philanthropy and ESG investing sectors.
Also Read: Big Pharma's Weight Loss Drugs Vs. Snacking Industry: Who Will Prevail?
Novo Nordisk's share price has ...